Nasdaq auph.

30 июн. 2023 г. ... On today's stock market, AUPH stock jumped 5.7% to close at 9.68. AUPH Stock: Sale, Merger Or Another Deal. Aurinia cautioned it has yet to ...

Nasdaq auph. Things To Know About Nasdaq auph.

Nov 29, 2023 · 2 analysts have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View analysts price targets for AUPH or ... On November 2, 2023, Aurinia Pharmaceuticals Inc ( NASDAQ:AUPH) released its financial results for the third quarter and nine months ended September 30, 2023. The company reported a significant ...The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00. Learn more on AUPH's analyst rating history. Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors?Find the latest news headlines from Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...

Sep 27, 2023 · It has been quite some time since we last took a look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). This small biopharma has been somewhat of a roller coaster ride for its shareholders in recent ...

What happened. Shares of the autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) are poised for a tough session today. Ahead of the opening bell, the drugmaker's share price ...Aurinia Pharmaceuticals Inc stock price live 8.64, this page displays NASDAQ AUPH stock exchange data. View the AUPH premarket stock price ahead of the market session or assess the after hours quote.

2 analysts have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View analysts price targets for AUPH or ...The new research reports from Fundamental Markets, available for free download at the links above, examine Shinhan Financial Group Co Ltd (NYSE:SHG), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH ...December 4, 2023. Company. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a beta value of 1.39 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $1.27B, closed the recent trade at $8.82 per share which meant it lost -$0.24 on the day or -2.60% during that session.NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...

Analyst's Opinion · Consensus Rating. Aurinia Pharmaceuticals has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...

Aurinia Pharmaceuticals AUPH stock was up about 11% on Tuesday after the company announced that the United States Patent and Trademark Office (USPTO) issued a new and refined method-of-use patent ...

May 22, 2023 · Last month, AUPH's second largest shareholder, MKT Capital, which holds 4.2% of the stock, wrote a scathing letter to shareholders, calling to withdraw support for CEO Peter Greenleaf, board ... On November 28, 2023, AUPH’s average trading volume was 1.85M shares. AUPH) stock’s latest price update. The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has plunged by -6.87 when compared to previous closing price of 9.17, but the company has seen a -0.70% decline in its stock price over the last five trading sessions.Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.9th Floor. Toronto, ON M5J 2Y1. Canada. T: +1-514-982-7555. [email protected]. https://www.computershare.com. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet …Discover historical prices for AUPH stock on Yahoo Finance. View daily, weekly or monthly format back to when Aurinia Pharmaceuticals Inc. stock was issued.Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ...

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars. 9.28.Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.On the other hand Veracyte Inc (NASDAQ:VCYT) is the least popular one with only 12 bullish hedge fund positions. Fitbit Inc (NYSE:FIT) is not the most popular stock in this group but hedge fund ...2 analysts have issued twelve-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 62.8% from the stock's current price. View analysts price targets for AUPH or ...

Sep 27, 2023 · It has been quite some time since we last took a look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). This small biopharma has been somewhat of a roller coaster ride for its shareholders in recent ...

Shares of NASDAQ:AUPH opened at $9.06 on Friday. The company has a market cap of $1.30 billion, a P/E ratio of -17.09 and a beta of 1.25. The company has a debt-to-equity ratio of 0.18, a current ...View Inc. (NASDAQ:VIEW) has a beta value of 0.59 and has seen 11.47 million shares traded in the recent trading session. The company, currently valued at $6.84M, closed the recent trade at $1.68 per share which meant it gained $0.65 on the day or 63.11% during that session. ... Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a …NASDAQ:AUPH. Press Releases. May 17, 2023. Aurinia Announces 2023 Annual General Meeting Results May 09, 2023. Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS ...A. Aurinia Pharmaceuticals ( AUPH) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 2, 2023 for Q3 and the Actual Revenue was $54 ...Aurinia Pharmaceuticals (NASDAQ: AUPH) reversed an earlier decline and is now up 3.4% after a report indicated Biogen (NASDAQ: BIIB) could potentially look to target the company. Aurinia ( AUPH ...Aurinia Pharmaceuticals AUPH stock was up about 11% on Tuesday after the company announced that the United States Patent and Trademark Office (USPTO) issued a new and refined method-of-use patent ...The FDA is scheduled to rule on Aurinia Pharmaceuticals Inc's (NASDAQ:AUPH) voclosporin as a treatment option for lupus nephritis. SHARE THIS POST. FACEBOOK. TWITTER. EMAIL. COPY LINK.Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a good speculative biotech play to look into. That's because it already has received FDA approval of LUPKYNIS™ as an oral treatment for adult ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.

October 30, 2023 at 7:26 AM · 3 min read We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s ( NASDAQ:AUPH) business as it appears the company …

According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Avid Bioservices Inc (NASDAQ:CDMO)’s Major holders. Insiders own 0.82% of the company shares, while shares held by institutions stand at 108.12% with a share float percentage of 109.02%. Investors are also buoyed by the number of investors in a company, with Avid Bioservices Inc having a total of 253 institutions that hold shares in the company.Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ...NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 ...Sinovac Biotech Ltd. 0.00. -6.47. -100.00%. Get Aurinia Pharmaceuticals Inc (AUPH:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Nov. 20, 2023, 12:38 PM. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are trading higher, adding to gains of more than 17% over the last week. The stock has been trending higher since the ...SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7 ...Real time Aurinia Pharmaceuticals (AUPH) stock price quote, stock graph, news & analysis.We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) business as it appears the company may be on the cusp of a …Back to AUPH Overview. Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is ...

Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Option Chain | Nasdaq. Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest ... It has been quite some time since we last took a look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). This small biopharma has been somewhat of a roller coaster ride for its shareholders in recent ...NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Instagram:https://instagram. how to earn crypto for freezcnex dividend date spy1921 silver morgan dollar value Dr_Microbe. This article is a follow-up to my previous coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) and as such may run a little shorter than earlier ones.In particular, today, I'd like to ...NASDAQ: AUPH Aurinia Pharmaceuticals. Market Cap. $1B. Today's Change (2.09%) $0.18. Current Price. ... (AUPH 2.09%) rose by as much as 13.2% in early morning trading Friday. The biotech's shares ... stock chart appclassic car investments Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has seen a decrease in hedge fund interest in recent months. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was in 24 hedge funds' portfolios at the end of ... 1964 half dollar worth Mar 9, 2023 · 9.24. +0.64. +7.44%. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter ... Aurinia Pharmaceuticals (NASDAQ:AUPH) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst …